RAPT Therapeutics, Inc.
RAPT
$0.7479
-$0.1309-14.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.81% | 24.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -64.63% | 175.24% | |||
| Operating Income | 64.63% | -175.24% | |||
| Income Before Tax | 67.76% | -188.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 67.76% | -188.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.76% | -188.89% | |||
| EBIT | 64.63% | -175.24% | |||
| EBITDA | 64.91% | -177.96% | |||
| EPS Basic | 93.01% | -140.71% | |||
| Normalized Basic EPS | 92.80% | -143.13% | |||
| EPS Diluted | 93.01% | -140.71% | |||
| Normalized Diluted EPS | 92.80% | -143.13% | |||
| Average Basic Shares Outstanding | 361.39% | 20.01% | |||
| Average Diluted Shares Outstanding | 361.39% | 20.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||